BeiGene gets FDA accelerated approval for Brukinsa combo to treat R/R FL
The approval was based on the overall response rate (ORR) from the ROSEWOOD study in which ORR was…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Mar 24
The approval was based on the overall response rate (ORR) from the ROSEWOOD study in which ORR was…
07 Mar 24
The investment, announced by the UK government as part of Finance Minister Jeremy Hunt's spring budget, is expected…
29 Feb 24
The FDA has set a PDUFA target action date of 28 August 2024 for the investigational, Aldose Reductase…
29 Feb 24
FDA-approved generic provides cost-effective option for treating cancer
28 Feb 24
Under the agreement, Italy-based Zambon will seek regulatory approval and market IPX203 in the European Union, UK, and…
28 Feb 24
AbbVie seeks approval for epcoritamab to treat adults with relapsed or refractory (R/R) FL after two or more…
28 Feb 24
The FDA approved Exblifep (cefepime/enmetazobactam) based on a comprehensive set of clinical data showing the drug's efficacy against…
28 Feb 24
The BTD for NVL-520 is based on the preliminary safety and activity of NVL-520 in heavily pretreated patients…
26 Feb 24
In the trial, a 16-week course of omalizumab enhanced the quantity of peanut, tree nut, egg, milk, and…
26 Feb 24
The typhoid vaccine was developed under a collaborative effort between the company and the International Vaccine Institute and…